Rznomics Inc, a South Korea based biopharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company's RZ-001 intended for the treatment of patients with Glioblastoma (GBM).
GBM is known as the most malignant tumour in Central Nervous system with high mortality rate but lacks effective therapies. RZ-001, the RNA replacement enzyme-based cancer gene therapy for the treatment of GBM, targets and cleaves hTERT mRNA and replaces the mRNA with the therapeutic gene RNA. This induces anti-cancer activity and cytotoxic effect by trans-ligating an HSVtk-encoding sequence into the reprogrammed hTERT mRNA. The company says that RZ-001 has demonstrated very promising responses in preclinical studies in which an enhanced anti-cancer efficacy and a higher survival rate was observed.
Rznomics received Phase I/IIa IND approval for RZ-001 from the FDA and the South Korean Ministry of Food and Drug Safety (MFDS) in Glioblastoma and the clinical trial will investigate the safety, tolerability, and efficacy of RZ-001 in patients with GBM. Subjects will be treated with RZ-001 according to the planned dose escalation design.
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Rznomics's RZ-001receives US FDA Fast Track Designation
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation